‘The CobOral branding and additional patent filings reflect the high level of interest from partners inside our CobOral and CobaCyte medication delivery platforms,’ mentioned Jeffrey B. Davis, President and CEO, Access Pharmaceuticals, Inc.’ Related StoriesNew RNA check of blood platelets can be used to detect area of cancerStudy shows uncommon HER2 missense mutations do not spread breasts cancer on their ownSausages With Antioxidants From Berries TO AVOID CancerAccess continues to create significant progress with its proprietary CobOral delivery technology.Blatt, Ph.D., Chief and Founder Executive Officer of Alios BioPharma. For more than a 10 years, Vertex is a leader in the advancement of new methods for dealing with hepatitis C, and we’ve the potential to make an all-oral together, interferon-free, mixture therapy that could improve the safety, simplicity and efficacy of administration for patients. We look forward to initiating clinical development this year later. The recent authorization of INCIVEK was a milestone in hepatitis C care, and today’s announcement underscores our long-term commitment to further improving the treating this disease with new combinations of medicines, said Peter Mueller, Ph.D., Chief Scientific Executive and Officer Vice President of Global Research and Development at Vertex.